Results 1 to 10 of about 1,580 (184)

Paradoxical Rise in Pulmonary Artery Pressure Following Successful Mavacamten Therapy for Obstructive Hypertrophic Cardiomyopathy: A Case Report [PDF]

Clinical Case Reports
A paradoxical rise in pulmonary artery pressure on follow‐up echocardiography after successful mavacamten therapy for obstructive hypertrophic cardiomyopathy (oHCM) prompted right heart catheterization, which demonstrated combined pre‐ and post‐capillary
Mengdian Zhang
doaj   +3 more sources

Early Insights on Mavacamten Usage in Canada: A Retrospective Cohort Study of the Mavacamten Patient Support Program [PDF]

CJC Open
Background: Only a limited amount of real-world data are available on the demographic and clinical characteristics of adult patients with obstructive hypertrophic cardiomyopathy (oHCM) treated with mavacamten in Canada.
Kevin Ong, MD, Patrick Garceau, MD, Andrew M. Crean, MD, Andrew D. Moeller, MD, Lou Kolman, MD, Stephanie Corriveau, PhD, Florence Brellier, PhD, Christina Wong, MHSc, Michael R. Ward, MD, PhD   +8 more
doaj   +3 more sources

Mavacamten in Chinese Patients with Obstructive Hypertrophic Cardiomyopathy: Patient-Reported Health Status Analysis up to 78 Weeks in the EXPLORER-CN Study [PDF]

Cardiology and Therapy
Introduction Improvement of symptoms, physical function, and quality of life is one treatment goal for patients with obstructive hypertrophic cardiomyopathy (HCM).
Zhuang Tian, Xiaoyan Li, Liwen Li, Qing Zhang, Jian’an Wang, Yunqi Shi, Daoquan Peng, Wei Ma, Ping Yang, Xiang Cheng, Wei Jin, Fang Wang, Arteid Memaj, Yimeng Xie, Beth Pan, Victoria Florea, Jing Zheng, Yue Zhong, Shuyang Zhang   +18 more
doaj   +2 more sources

Mavacamten in Obstructive Hypertrophic Cardiomyopathy: National Insights on Access and Safety Profile From Real‐World Data [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Mavacamten improves symptoms in obstructive hypertrophic cardiomyopathy, but real‐world prescription patterns, safety profile, and the effect of atrial fibrillation (AF) on outcomes remain unclear. Methods An observational multicenter analysis
Ayman R. Fath, Amro Aglan, Srihari S. Naidu, Michael J. Mader, Robert J. Chilton, Islam Y. Elgendy, Martin S. Maron, Ethan J. Rowin   +7 more
doaj   +2 more sources

Mavacamten

JACC: Advances
Matthew W. Martinez, MD, Dewey Seto, BSBA, Michael Cheung, DHSc, Michele Coiro, MBA, Niki Patel, PharmD, Arnaud Bastien, MD, Jeffrey Lockman, PhD, Sonia Afsari, MD, Milind Y. Desai, MD, MBA   +8 more
doaj   +11 more sources

Case Report: Mavacamten in mid-ventricular and apical hypertrophic cardiomyopathy—a case of targeted therapy beyond left ventricular outflow tract obstruction [PDF]

Frontiers in Medicine
BackgroundMavacamten targets cardiac myosin ATPase, reducing the formation of actin-myosin cross-bridges, which alleviates excessive myocardial contraction and improves diastolic function.
Lijia Yang, Hongyan Dai, Yuanyuan Rong
doaj   +2 more sources

Mavacamten and atrial fibrillation: assessing the risk through FAERS and meta-analysis [PDF]

BMC Cardiovascular Disorders
Background Mavacamten is a novel selective cardiac myosin inhibitor indicated for patients with obstructive hypertrophic cardiomyopathy (oHCM). Given its negative inotropic properties, which theoretically reduce myocardial contractility and affect left ...
Lingqing Ding, Xinhang Liao, Yongkuan Yang, Congqin Chen, Jie Xiao   +4 more
doaj   +2 more sources

Efficacy and safety of mavacamten in non-obstructive hypertrophic cardiomyopathy: A systematic review and meta-analysis of randomized trials [PDF]

International Journal of Cardiology: Heart & Vasculature
Background: Non-obstructive hypertrophic cardiomyopathy (nHCM) remains a therapeutic challenge, with limited pharmacological options beyond symptomatic management.
Muhammad Abdullah, Husna Irfan Thalib, Mustafa Bin Tahir, Noman Khalid, Ahmad Mushtaq, Muhammad Adil Afzal, Michael D Moore, Nagaraja Sharma, Salman Muddassir, Michael Parker Ayers, Mazen Albaghdadi, Wilbert S. Aronow   +11 more
doaj   +2 more sources

Comparison of Diastolic Function Parameters After Alcohol Septal Ablation and Mavacamten Therapy in Obstructive Hypertrophic Cardiomyopathy [PDF]

Journal of Cardiovascular Development and Disease
Cardiac myosin inhibitors have been shown to improve diastolic function in patients with obstructive hypertrophic cardiomyopathy (HCM). Comparative studies to evaluate the diastolic effects of mavacamten versus alcohol septal ablation (ASA) have yet to ...
Danish Saleh, Ellis Y. Kim, Kifah Hussain, Ashraf Samhan, Meilynn Shi, Zhiying Meng, Elizabeth Schormann, Parmeen Bindra, Baljash Cheema, Dominic E. Fullenkamp, Abigail S. Baldridge, Jyothy J. Puthumana, Vera H. Rigolin, Paul C. Cremer, James D. Flaherty, Lubna Choudhury   +15 more
doaj   +2 more sources

Eighteen‐Month Real‐World Experience Using Mavacamten for Treatment of Obstructive Hypertrophic Cardiomyopathy in a Racially Diverse Population

Journal of the American Heart Association
Background Patients with obstructive hypertrophic cardiomyopathy have increased symptomatic burden. Mavacamten was recently approved for treatment of obstructive hypertrophic cardiomyopathy based on 2 randomized controlled trials.
Richard T Carrick, JOSÉ A Madrazo, Katherine C Wu   +2 more
exaly   +3 more sources